TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24706353

Group type: EXPERIMENTAL
Intervention: Prophylactic medication (brimonidine and timolol) instilled 5 minutes before injection
Number of subjects: 141

Group type: COMPARATOR
Intervention: No prophylactic medication
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Vitreous reflux presence
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: All groups (with and without prophylactic medication)
Number of subjects: 141
Study: 23964445

Group type: EXPERIMENTAL
Intervention: One gram of powdered ginger per day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 20595646

Group type: EXPERIMENTAL
Intervention: n‐3 group (2.5 g/d of n‐3 LCPUFA, with 1.67 g of EPA and 0.83 g of DHA)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 46
Study: 16672187

Group type: EXPERIMENTAL
Intervention: Tai Chi (TC) training
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control training
Number of subjects: 22
Study: 15660732

Group type: EXPERIMENTAL
Intervention: Nateglinide 120 mg (t.i.d., n = 33)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo (n = 14)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Nateglinide 120 mg (t.i.d.)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 12092887

Group type: EXPERIMENTAL
Intervention: Soft midsole shoes
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Medium midsole shoes
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Hard midsole shoes
Number of subjects: 24

Group type: COMPARATOR
Intervention: Downhill running (irrespective of midsole durometer)
Number of subjects: 24
Study: 10549836

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate every 6 hours (Group A)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate every 12 hours (Group B)
Number of subjects: 66
Study: 7558223

Group type: EXPERIMENTAL
Intervention: Synthetic human brain natriuretic peptide‐32 (0.25 pmol/kg per minute for the first hour and 0.50 pmol/kg per minute for the second hour)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Synthetic human brain natriuretic peptide‐32
Number of subjects: 6
Study: 1993790

Group type: EXPERIMENTAL
Intervention: DDDR (dual chamber universal rate‐responsive)
Number of subjects: 22

Group type: COMPARATOR
Intervention: VVIR (ventricular demand rate‐responsive)
Number of subjects: 22

Group type: COMPARATOR
Intervention: VVIR and DDIR modes
Number of subjects: 22

Group type: COMPARATOR
Intervention: DDDD (dual chamber universal)
Number of subjects: 22

Group type: COMPARATOR
Intervention: VVIR mode
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: DDIR
Number of subjects: 22

Group type: COMPARATOR
Intervention: VVIR
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: DDD mode
Number of subjects: 22
Study: 7045365

Group type: EXPERIMENTAL
Intervention: Prone posture for four hours
Number of subjects: 50

Group type: COMPARATOR
Intervention: 30 degrees head down tilt for 30 minutes followed by supine posture for 3 1/2 hours
Number of subjects: 50
Study: 31522849

Group type: EXPERIMENTAL
Intervention: Peanut-0 group (4000 mg peanut protein through to week 104, then discontinued)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Peanut-300 group (4000 mg peanut protein through to week 104, then 300 mg daily for 52 weeks)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo group (oat flour)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Peanut-0 group
Number of subjects: 120
Study: 28002873

Group type: EXPERIMENTAL
Intervention: Pupil dilation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Undilated eye
Number of subjects: 30
Study: 25682436

Group type: EXPERIMENTAL
Intervention: ACEi/ARB
Number of subjects: 1509

Group type: COMPARATOR
Intervention: No ACEi/ARB
Number of subjects: 1509
Study: 24344787

Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl solution (TFS) 2.7 mg/kg applied 2-4 hours prior to surgery
Number of subjects: 502

Group type: COMPARATOR
Intervention: Oxymorphone hydrochloride 0.22 mg/kg administered subcutaneously 2-4 hours prior to surgery and every 6 hours for 90 hours
Number of subjects: 502
Study: 23066159

Group type: EXPERIMENTAL
Intervention: FSI within 3 years of menarche
Number of subjects: 504

Group type: COMPARATOR
Intervention: Postponed FSI beyond 3 years of menarche
Number of subjects: 504
Study: 19597964

Group type: EXPERIMENTAL
Intervention: Treatment Outcome Score (TOS)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Mean Symptom Complex Severity (MSCS) score
Number of subjects: 73
Study: 17631256

Group type: EXPERIMENTAL
Intervention: Reflexology
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 30
Study: 15688096

Group type: EXPERIMENTAL
Intervention: Circular excisions
Number of subjects: 56

Group type: COMPARATOR
Intervention: Elliptical excisions
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Circular excisions without complications
Number of subjects: 56

Group type: COMPARATOR
Intervention: Elliptical excisions without complications
Number of subjects: 56
Study: 12407029

Group type: EXPERIMENTAL
Intervention: Cryopreservation of all embryos
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Elective cryopreservation of all embryos
Number of subjects: 0

Group type: COMPARATOR
Intervention: i.v. human albumin administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fresh embryo transfer
Number of subjects: 0
Study: 9809088

Group type: EXPERIMENTAL
Intervention: Desflurane/N2O at 1 and 1.5 MAC
Number of subjects: 25

Group type: COMPARATOR
Intervention: Isoflurane/N2O at 1 and 1.5 MAC
Number of subjects: 25
Study: 7544439

Group type: EXPERIMENTAL
Intervention: Adenoviral vector containing normal CFTR cDNA (doses: 1, 10, 100, 1000)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Adenoviral vector (highest dose)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Vehicle alone (control)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lower doses of adenoviral vector
Number of subjects: 12
Study: 2494949

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 4236

Group type: COMPARATOR
Intervention: Telephone method for random allocation
Number of subjects: 4236
Study: 367570

Group type: EXPERIMENTAL
Intervention: BOPP (4-drug regimen)
Number of subjects: 537

Group type: EXPERIMENTAL
Intervention: MOPP (4-drug regimen)
Number of subjects: 537

Group type: COMPARATOR
Intervention: BOP (3-drug regimen)
Number of subjects: 537

Group type: COMPARATOR
Intervention: OPP (3-drug regimen)
Number of subjects: 537

Group type: COMPARATOR
Intervention: Maintenance chemotherapy (vinblastine, chlorambucil, or chlorambucil plus monthly vincristine + prednisone)
Number of subjects: 537

Group type: EXPERIMENTAL
Intervention: 4-drug programs (BOPP and MOPP)
Number of subjects: 537

Group type: EXPERIMENTAL
Intervention: Patients who obtained CR
Number of subjects: 537
Study: 31594858

Group type: EXPERIMENTAL
Intervention: DMD mutations downstream of DMD exon 45
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Boys of DMD carrier mothers
Number of subjects: 196
Study: 28246176

Group type: EXPERIMENTAL
Intervention: Intralipid postconditioning (ILPC) group received an intravenous infusion of 20% intralipid (2 mL/kg) just 10 min before aortic cross‐unclamping
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group received an equivalent volume of normal saline
Number of subjects: 73
Study: 26084032

Group type: EXPERIMENTAL
Intervention: HRM diet
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: HRM + HAMSB diet
Number of subjects: 23
Study: 24565127

Group type: EXPERIMENTAL
Intervention: Bupivacaine (10mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Levobupivacaine (10mg)
Number of subjects: 60
Study: 22998737

Group type: EXPERIMENTAL
Intervention: Weight loss and decreased fasting insulin
Number of subjects: 339

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 339
Study: 19201286

Group type: EXPERIMENTAL
Intervention: 3-ounce water swallow challenge
Number of subjects: 56
Study: 17966842

Group type: EXPERIMENTAL
Intervention: Insulin therapy for 5 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (6 healthy subjects)
Number of subjects: 10
Study: 15363006

Group type: EXPERIMENTAL
Intervention: Hospital group (Hospital/Home + Hospital/Community)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Community group (Community/Community)
Number of subjects: 43
Study: 11405501

Group type: EXPERIMENTAL
Intervention: IVUS guided PCI
Number of subjects: 108

Group type: COMPARATOR
Intervention: CAG guided PCI
Number of subjects: 108
Study: 9534083

Group type: EXPERIMENTAL
Intervention: Liquid carbohydrate (CHO) ingestion during exercise
Number of subjects: 8

Group type: COMPARATOR
Intervention: Solid carbohydrate (SCE) ingestion with water
Number of subjects: 8

Group type: COMPARATOR
Intervention: Solid carbohydrate (SCA) ingestion with ad libitum water
Number of subjects: 8
Study: 7528485

Group type: EXPERIMENTAL
Intervention: 60 mg/d of carbimazole
Number of subjects: 197

Group type: COMPARATOR
Intervention: Minimal dose required to obtain euthyroidism (low dose)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: High dose (60 mg/d)
Number of subjects: 197
Study: 2894749

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 31901245

Group type: EXPERIMENTAL
Intervention: Strict glycemic control (target BG 80-120 mg/dL)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional glycemic control (target BG 180-200 mg/dL)
Number of subjects: 100
Study: 29742702

Group type: EXPERIMENTAL
Intervention: Spore Powder of Ganoderma Lucidum (SPGL)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 28230835

Group type: EXPERIMENTAL
Intervention: Gradual wean (reduction in pressure by 1 cm every 8 hours until 3 cm H2O)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Sudden wean (one time NCPAP removal to room air)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Gradual wean
Number of subjects: 70

Group type: COMPARATOR
Intervention: Sudden wean
Number of subjects: 70
Study: 25219423

Group type: EXPERIMENTAL
Intervention: 6-month weekly group intervention plus six monthly maintenance sessions (N=104)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care (N=96)
Number of subjects: 200
Study: 23371774

Group type: EXPERIMENTAL
Intervention: Inductive reasoning with no time pressure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inductive reasoning with time pressure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recognition memory
Number of subjects: 0
Study: 22025233

Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 300

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 300
Study: 18458360

Group type: EXPERIMENTAL
Intervention: Opuntia ficus indica (OFI)
Number of subjects: 10
Study: 16532466

Group type: EXPERIMENTAL
Intervention: Oxybutynin transdermal patch
Number of subjects: 659

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 659
Study: 14501397

Group type: EXPERIMENTAL
Intervention: Moist Exposed Burn Ointment (MEBO)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 115
Study: 11186806

Group type: EXPERIMENTAL
Intervention: Randomized controlled trials
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Quasi-randomized trials
Number of subjects: 11

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 11
Study: 9200250

Group type: EXPERIMENTAL
Intervention: Walking with Power Poles
Number of subjects: 32

Group type: COMPARATOR
Intervention: Walking without Power Poles
Number of subjects: 32
Study: 1439447

Group type: EXPERIMENTAL
Intervention: Immediate node dissection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed node dissection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgical approach for axial melanomas
Number of subjects: 0
Study: 3095220

Group type: EXPERIMENTAL
Intervention: Lysine aspirin (150, 300, 600 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Soluble aspirin (150, 300, 600 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Conventional aspirin (150, 300, 600 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 29705075

Group type: EXPERIMENTAL
Intervention: Continuous catheter femoral nerve block (cFNB)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Single injection femoral nerve block (sFNB)
Number of subjects: 85

Group type: COMPARATOR
Intervention: sFNB
Number of subjects: 85
Study: 27694596

Group type: EXPERIMENTAL
Intervention: Ring fixator
Number of subjects: 70

Group type: COMPARATOR
Intervention: Rail fixator
Number of subjects: 70
Study: 24519922

Group type: EXPERIMENTAL
Intervention: Overground walking training
Number of subjects: 20

Group type: COMPARATOR
Intervention: Body weight‐supported treadmill training
Number of subjects: 20
Study: 22402472

Group type: EXPERIMENTAL
Intervention: Watermelon extract supplementation (L‐citrulline/L‐arginine, 6 g daily)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 20304805

Group type: EXPERIMENTAL
Intervention: 46/1 JAK2 haplotype in V617F-positive cases
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: 46/1 JAK2 haplotype in cases without V617F
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: 46/1 JAK2 haplotype in MPL-positive, V617F-negative cases
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: 46/1 JAK2 haplotype in JAK2 exon 12 mutated cases
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: 46/1 JAK2 haplotype in MPL-mutated cases
Number of subjects: 404

Group type: COMPARATOR
Intervention: Comparison of JAK2 on 46/1 versus other haplotypes
Number of subjects: 404
Study: 18365946

Group type: EXPERIMENTAL
Intervention: Parental support intervention
Number of subjects: 59

Group type: COMPARATOR
Intervention: Minimum behavioral intervention
Number of subjects: 59
Study: 16476804

Group type: EXPERIMENTAL
Intervention: Pyridostigmine bromide 60 mg
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Pyridostigmine bromide 60 mg and midodrine hydrochloride 5 mg
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 12962458

Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 10988016

Group type: EXPERIMENTAL
Intervention: Lovastatin 20-40 mg daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9187174

Group type: EXPERIMENTAL
Intervention: X Hz group (n=19)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 5 Hz group (n=19)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Normothermic group (n=15)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Hypothermic group (n=15)
Number of subjects: 68
Study: 1645103

Group type: EXPERIMENTAL
Intervention: Alcohol (0 to 1.0 g/kg) administered alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cocaine (4 to 96 mg/70 kg) administered alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cocaine and alcohol administered in combination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 0
Study: 2409325

Group type: EXPERIMENTAL
Intervention: High-dose methotrexate (HD-MTX), adriblastine (ADR), and cyclophosphamide (CP) for 12 months in COSS-77.
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Doubled dose of methotrexate (MTX), cisplatinum (CPL) or bleomycin + CP + dactinomycin (BCD) in addition to MTX and ADR for 8 months in COSS-80.
Number of subjects: 215

Group type: COMPARATOR
Intervention: COSS-80 group (CPL and BCD arms).
Number of subjects: 215

Group type: COMPARATOR
Intervention: COSS-80 group (with and without fibroblaste-interferon (IF)).
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: COSS-80 group (young patients less than 12 years and male patients).
Number of subjects: 215
Study: 29498170

Group type: EXPERIMENTAL
Intervention: Doxazosin (8 mg/day, N = 47)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo (N = 29)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Doxazosin (8 mg/day) in T-allele carriers (CT/TT)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo in CC genotype group
Number of subjects: 76
Study: 30446596

Group type: EXPERIMENTAL
Intervention: Galcanezumab 120 mg
Number of subjects: 1113

Group type: EXPERIMENTAL
Intervention: Galcanezumab 240 mg
Number of subjects: 1113

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1113
Study: 27920083

Group type: EXPERIMENTAL
Intervention: Bedtime dosing (BD) of enalapril (20 mg at bedtime)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Morning dosing (MD) of enalapril (20 mg in the morning)
Number of subjects: 24
Study: 24760603

Group type: EXPERIMENTAL
Intervention: Timolol 0.1% gel
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Timolol 0.5% eyedrops
Number of subjects: 70

Group type: COMPARATOR
Intervention: No treatment (Control group)
Number of subjects: 70
Study: 22790645

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU) with 10% fat meal
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU) with 20% fat meal
Number of subjects: 16

Group type: COMPARATOR
Intervention: Testosterone undecanoate (TU) with 30% fat meal (normal-fat meal)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU) with 50% fat meal
Number of subjects: 16

Group type: COMPARATOR
Intervention: Testosterone undecanoate (TU) fasting
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU) with very-low-fat meal (10% fat)
Number of subjects: 16
Study: 18799373

Group type: EXPERIMENTAL
Intervention: Forceps without needle
Number of subjects: 24

Group type: COMPARATOR
Intervention: Forceps with needles
Number of subjects: 24
Study: 17460336

Group type: EXPERIMENTAL
Intervention: CHO+P+A beverage (10 mL/kg body weight)
Number of subjects: 23

Group type: COMPARATOR
Intervention: CHO beverage (10 mL/kg body weight)
Number of subjects: 23

Group type: COMPARATOR
Intervention: CHO+P+A vs CHO
Number of subjects: 23

Group type: COMPARATOR
Intervention: Running performance after CHO and CHO+P+A
Number of subjects: 23

Group type: COMPARATOR
Intervention: Correlation with treatment differences
Number of subjects: 23
Study: 14981007

Group type: EXPERIMENTAL
Intervention: CO2 insufflation via a gas diffuser
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no CO2 insufflation)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: CO2 insufflation
Number of subjects: 20
Study: 11548917

Group type: EXPERIMENTAL
Intervention: HYPO (fluid intake restricted)
Number of subjects: 7

Group type: COMPARATOR
Intervention: EUH (forced to drink to maintain euhydration)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: HYPO
Number of subjects: 7

Group type: COMPARATOR
Intervention: EUH
Number of subjects: 7
Study: 9669014

Group type: EXPERIMENTAL
Intervention: Low dose tranexamic acid (20 mg.kg‐1)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Medium dose tranexamic acid (50 mg.kg‐1)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: High dose tranexamic acid (100 mg.kg‐1)
Number of subjects: 220
Study: 8055263

Group type: EXPERIMENTAL
Intervention: Cannabinoids (marijuana)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 11039036

Group type: EXPERIMENTAL
Intervention: Antimicrobial varnish applied to teeth
Number of subjects: 33
Study: 31103972

Group type: EXPERIMENTAL
Intervention: Selenium and anti-tuberculosis drug
Number of subjects: 80

Group type: COMPARATOR
Intervention: Anti-tuberculosis drug
Number of subjects: 80
Study: 28384390

Group type: EXPERIMENTAL
Intervention: Multicomponent Restraint Reduction Program (MRRP) including three educational sessions and two unit-based consultations
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 122
Study: 25948781

Group type: EXPERIMENTAL
Intervention: High WHtR with inflammation
Number of subjects: 8068

Group type: EXPERIMENTAL
Intervention: High WHtR without inflammation
Number of subjects: 8068
Study: 23265088

Group type: EXPERIMENTAL
Intervention: Mindfulness Training (MT)
Number of subjects: 33
Study: 21212501

Group type: EXPERIMENTAL
Intervention: Nonelastic sports tape
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Kinesio Tape
Number of subjects: 51

Group type: COMPARATOR
Intervention: No ankle taping
Number of subjects: 51
Study: 19506571

Group type: EXPERIMENTAL
Intervention: Levetiracetam (500 mg b.i.d. to a maximum of 1500 mg b.i.d.)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 36
Study: 16155355

Group type: EXPERIMENTAL
Intervention: Specific inspiratory muscle training (SIMT)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 28
Study: 15202302

Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass surgery (OPCAB)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Cardiopulmonary bypass surgery (ONCAB)
Number of subjects: 75
Study: 11419451

Group type: EXPERIMENTAL
Intervention: 5-FU plus FA plus LEV (arm B, n = 283)
Number of subjects: 813

Group type: COMPARATOR
Intervention: 5-FU plus LEV (arm A, n = 279)
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: 5-FU plus LEV with IFN-alpha (arm C, n = 251)
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: All arms combined
Number of subjects: 813

Group type: COMPARATOR
Intervention: 5-FU plus LEV (arm A)
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: 5-FU plus FA plus LEV (arm B)
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: 5-FU plus LEV with IFN-alpha (arm C)
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 813
Study: 9240989

Group type: EXPERIMENTAL
Intervention: Ankle disk training for 8 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study: 8306514

Group type: EXPERIMENTAL
Intervention: Low work-rate exercise (LWE) for 10 weeks
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High work-rate exercise (HWE) for 10 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Comparison of LWE and HWE
Number of subjects: 10
Study: 3028596

Group type: EXPERIMENTAL
Intervention: Alternating chemotherapy (EVI, PAV, CMC)
Number of subjects: 306

Group type: COMPARATOR
Intervention: Sequential chemotherapy (CAV)
Number of subjects: 306